What KORU Medical’s RYSTIGGO delivery clearance means for subcutaneous infusion models
KORU Medical’s FreedomEDGE gets FDA clearance for RYSTIGGO delivery in clinics. Find out how this expands access to gMG therapy and reshapes infusion workflows.
Can subcutaneous infusion disrupt oncology workflows? Inside KORU Medical’s 510(k) strategy for FreedomEDGE
KORU Medical’s 510(k) filing for FreedomEDGE with PHESGO could reshape subcutaneous cancer therapy. Find out what this means for oncology care delivery.
KORU Medical seeks FDA clearance to expand FreedomEDGE into HER2+ breast cancer treatment
KORU Medical’s FDA filing to clear FreedomEDGE for PHESGO delivery could reshape cancer infusion workflows. Find out what it means for oncology care.